Advertisement

Topics

Siegfried Biologics GmbH Company Profile

04:43 EDT 21st June 2018 | BioPortfolio

Siegfried Biologics, a business unit of Siegfried Ltd., consists of the corporate office located in Zofingen, Switzerland dealing with biotechnological development projects and biopharmaceutical contract development as well as manufacturing premises located in Berlin, Germany. Siegfried Biologics GmbH is a globally focused and independent service provider in the field of biopharmaceutical contract development and GMP manufacturing. Services include the entire chemistry-manufacturing-control (CMC) value chain from gene synthesis to the production of active pharmaceutical ingredient proteins (API) for clinical trial phases I - III, using mammalian expression technology.
Since 2001, we have been in possession of a manufacturing license by the local health authority to produce biopharamceutical active ingredients for clinical trials.

The company, formerly Alpha Bioverfahrenstechnik GmbH, was founded in 1993 and is located in Kleinmachnow/Berlin. In 2002, the Siegfried Group acquired the majority of Alpha and renamed it Siegfried Biologics GmbH.

Location

Heinrich-Hertz-Strasse 1b
Kleinmachnow
14532
Germany

Contact

Phone: 49 33203 8047 0
Fax: 49 33203 8047 31
Email: info@siegfried-biologics.com


News Articles [667 Associated News Articles listed on BioPortfolio]

Siegfried Group: Change in the Executive Committee

Rudolf Hanko will step down as Chief Executive Officer of Siegfried Group on 31 December 2018. The Board of Directors appointed Wolfgang Wienand as new CEO of Siegfried Group with effect from 1 Januar...

Siegfried Congratulates Erica Vandell on New Leadership Role

As a Director on Siegfried's National Market Leadership Team, Vandell will continue to serve as a Leadership Advisor for Siegfried's clients, and will focus on Read more...

Wolfgang Wienand to Succeed Rudolf Hanko as CEO of Siegfried

Wolfgang Wienand has been appointed as new CEO of Siegfried with effect from Jan. 1, 2019. Rudolf Hanko, the group’s current CEO, will step down on Dec. 31, 2018. The board has decided to propos...

Siegfried Congratulates Tiffany Watts on New Leadership Role

As a Director on Siegfried's National Market Leadership Team, Watts will focus on business development and providing five-star service to her clients, who work with Read more...

Siegfried-Aktien nach Jahreszahlen klar leichter

Zürich (awp) - Die Aktien von Siegfried sind am Mittwoch mit relativ deutlichen Abgaben in den Handel gestartet. Der Pharmazulieferer hat mit seinen am Morgen publizierten Jahreszahlen die Erwartun.....

Keryx hires Siegfried to make Auryxia API

Keryx Biopharmaceuticals Inc has hired Siegfried Holding AG to make the API for its hyperphosphatemia drug Auryxia.

Siegfried-Chef Rudolf Hanko tritt per Ende 2018 zurück

(Meldung ausgebaut) Zofingen (awp) - Beim Pharmazulieferer Siegfried tritt der langjährige Konzernchef Rudolf Hanko per Ende 2018 zurück. Der Deutsche leitet das Unternehmen seit mehr als neun Jahr....

LDC opens branch in Munich

The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emph...

PubMed Articles [122 Associated PubMed Articles listed on BioPortfolio]

Dr W. H. R. Rivers: Siegfried Sassoon and Robert Graves' 'fathering friend'.

Biologics for pityriasis rubra pilaris treatment: a review of the literature.

Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease, often refractory to conventional therapies. The off-label use of biologics, such as anti-TNF, -IL-12/IL-23, -IL-17 ag...

Facilitated recruitment of mesenchymal stromal cells by bone marrow concentrate and platelet rich plasma.

Biologics containing growth factors are frequently used to enhance healing after musculoskeletal injuries. One mechanism of action is thought to be though the ability of biologics to induce homing and...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

Clinical Trials [118 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [782 Associated Companies listed on BioPortfolio]

Siegfried Biologics GmbH

Siegfried Biologics, a business unit of Siegfried Ltd., consists of the corporate office located in Zofingen, Switzerland dealing with biotechnological development projects and biopharmaceutical contr...

Siegfried Ltd

Siegfried Biologics, a business unit of Siegfried Ltd., consists of the corporate office located in Zofingen, Switzerland dealing with biotechnological development projects and biopharmaceutical contr...

Siegfried Holding AG

The Siegfried Group is a globally focused company listed on the Swiss Stock Exchange (SWX). The Siegfried Division with its three business units develops and produces pharmaceutical and biopharmaceuti...

Richard N. Siegfried, M.D., L.L.C., Comprehensive Pain Management

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

More Information about "Siegfried Biologics GmbH" on BioPortfolio

We have published hundreds of Siegfried Biologics GmbH news stories on BioPortfolio along with dozens of Siegfried Biologics GmbH Clinical Trials and PubMed Articles about Siegfried Biologics GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Siegfried Biologics GmbH Companies in our database. You can also find out about relevant Siegfried Biologics GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record